ZZPZH(SH:600436) Mei Ri Jing Ji Xin Wen·2025-12-09 16:55Core Viewpoint - The prominent investor Lin Yuan remains optimistic about the stock of Pian Zai Huang, stating that it is a valuable product that is hard to find, despite the company's recent poor financial performance [2]. Financial Performance - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.442 billion yuan, a year-on-year decline of 11.93% [2][3]. - The net profit attributable to shareholders was 2.129 billion yuan, down 20.74% year-on-year [2][3]. - In Q3 2025, the company achieved revenue of 2.064 billion yuan, a decrease of 26.28% compared to the same quarter last year, with a net profit of 687 million yuan, down 28.82% year-on-year [2][3]. Inventory and Market Value - The inventory increased to 6.16 billion yuan, reflecting a growth of 24.02% since the beginning of the year [2]. - The market value of Pian Zai Huang has significantly decreased, with its stock price dropping over 60% from its peak in 2021, resulting in a total market value of 101.1 billion yuan as of December 9, 2025 [3][4]. Product Pricing - The price of Pian Zai Huang's medicinal pills has dropped significantly, with current retail prices ranging from 614 yuan to 760 yuan, representing a decline of over 15% from the official retail price [4].